Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial
about
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal WomenNeoadjuvant endocrine therapy in breast cancer: current role and future perspectivesBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineMain controversies in breast cancerOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Rapid modulation of aromatase activity in the vertebrate brainAdjuvant exemestane with ovarian suppression in premenopausal breast cancer.Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomicsA randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.Competing risks of death in younger and older postmenopausal breast cancer patientsTreatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients.Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomyEffects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.Clinical utility of exemestane in the treatment of breast cancerA prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.Landscape of neoadjuvant therapy for breast cancerThe Globalization of Cooperative Groups.Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyAssociations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy VolunteersBisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!Adjuvant endocrine therapy in premenopausal women with breast cancer.Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.Osteoporosis and cancerPharmacogenomics of endocrine therapy in breast cancer.Skeletal manifestations of treatment of breast cancer.Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.Clinical studies examining the impact of obesity on breast cancer risk and prognosis.Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.New insights into endocrine therapy for young women with breast cancer.
P2860
Q26745464-B15D0E2A-33BE-4CCA-864D-0D7F1DA16BC1Q26773012-95E8A842-D642-4D2D-8C6C-2B8794613D7AQ26795493-16391436-526F-41A0-90A5-6CF6157F5F90Q27002430-8F7493BF-A53A-467F-9081-B8114F7B74C2Q27026673-E2BA8F29-AD2E-41B3-B52D-4B7B624AFA9CQ33698446-1EB38E7D-DCAB-4544-A150-8E35081489C3Q33873509-0B5EEFD8-860D-44AF-A09B-2F5B268D8B91Q34245992-2096ED98-4433-4534-B5D3-7CFDA1EBFAB5Q34265045-EB8BCABB-187C-4243-960D-33F94D09DDC1Q34347274-38181930-1379-4A49-9607-CFE43DB9CE1DQ34657626-37350320-4E7A-45EC-BF0E-09997388D3FBQ34903656-067FB805-F9BE-4B7C-9825-0749E1534C41Q35023875-EFB54E61-FA73-49AF-B2C3-BB12BABBDEE0Q35073191-BC07BE8C-CD88-4D9C-91DA-F23D0D2C6163Q35155647-CB4C7FD7-B86D-4872-AC5D-D64EFB924443Q35683807-17AC7AC4-3872-4D52-99A4-25BEBF52DB59Q35713616-B9BD7BDC-655E-433D-9A16-39B987FFBA49Q35794915-49CF1F75-35BB-4925-BC02-6EAC7738FA12Q36119749-4C1FAD42-456C-450F-AB33-45274969F620Q36140045-C1CD44B6-BA32-4641-AE45-03CB96A40828Q36377956-1C8CD0C7-9F7A-4727-B353-8AFBA73289F4Q36632405-E708D2D6-06E3-4CE2-B7AE-CBCC6CB118FFQ36658848-A77D73C3-1C80-4318-9320-87CB40AC0E3CQ36693164-2116CB3A-F8BF-4905-AAC4-20018483D939Q36728379-D9312C5E-6DB0-4133-B492-12AD445E903BQ36823146-418D6556-6D3E-4681-B229-9DC8CE7DEE2CQ36884366-B6E6CCB6-8B48-49B2-8AE1-E830C5A113FAQ36915182-388DBADE-A1FB-4D5E-995A-0B12C6B3C737Q36940755-A681DC6E-046B-4A47-83D9-185438A7B193Q36963360-262A4D34-4A92-4E48-BE41-F5159BB5F3C5Q36976772-B04F082C-EB8A-4FBA-9B47-865343B63692Q37025619-64AFC2FD-AA11-4D66-A20E-1060A5AB4D35Q37198504-C2C531B5-1832-4774-A16F-4ED9896FF1F6Q37588045-5588A264-68C6-4598-9D18-654636BF0ABEQ37630298-B2523E91-68B0-4127-BE68-71218205BC2DQ37696677-14321A8D-2F1D-4F56-B0E5-D820BC79946EQ37717870-7B2CD1A2-5587-4579-B7C5-A206963DA93EQ38162118-C3903559-778F-4190-A263-561360749F8EQ38374560-C2F750E8-DA55-46BA-A3C8-EF4E74E28A24Q38535371-FC9CB92D-68A8-4C78-9738-F6BF1496B0CF
P2860
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Exemestane versus anastrozole ...... zed controlled phase III trial
@ast
Exemestane versus anastrozole ...... zed controlled phase III trial
@en
type
label
Exemestane versus anastrozole ...... zed controlled phase III trial
@ast
Exemestane versus anastrozole ...... zed controlled phase III trial
@en
prefLabel
Exemestane versus anastrozole ...... zed controlled phase III trial
@ast
Exemestane versus anastrozole ...... zed controlled phase III trial
@en
P2093
P2860
P356
P1476
Exemestane versus anastrozole ...... zed controlled phase III trial
@en
P2093
Catherine Elliott
David B Johnson
David P D'Souza
Edith A Perez
G Thomas Budd
George W Sledge
Haji Chalchal
Istvan Lang
James N Ingle
Judy-Anne W Chapman
P2860
P304
P356
10.1200/JCO.2012.44.7805
P407
P577
2013-01-28T00:00:00Z